Gilles Salles, Johannes Duell, Eva González Barca, Olivier Tournilhac, Wojciech Jurczak, Anna Marina Liberati, Zsolt Nagy, Aleš Obr, Gianluca Gaidano, Marc André, Nagesh Kalakonda, Martin Dreyling, Johannes Weirather, Maren Dirnberger-Hertweck, Sumeet Ambarkhane, Günter Fingerle-Rowson, Kami Maddocks. Lancet Oncol 2020
Times Cited: 144
Times Cited: 144
Times Cited
Times Co-cited
Similarity
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Laurie H Sehn, Alex F Herrera, Christopher R Flowers, Manali K Kamdar, Andrew McMillan, Mark Hertzberg, Sarit Assouline, Tae Min Kim, Won Seog Kim, Muhit Ozcan,[...]. J Clin Oncol 2020
Laurie H Sehn, Alex F Herrera, Christopher R Flowers, Manali K Kamdar, Andrew McMillan, Mark Hertzberg, Sarit Assouline, Tae Min Kim, Won Seog Kim, Muhit Ozcan,[...]. J Clin Oncol 2020
62
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Stephen J Schuster, Michael R Bishop, Constantine S Tam, Edmund K Waller, Peter Borchmann, Joseph P McGuirk, Ulrich Jäger, Samantha Jaglowski, Charalambos Andreadis, Jason R Westin,[...]. N Engl J Med 2019
Stephen J Schuster, Michael R Bishop, Constantine S Tam, Edmund K Waller, Peter Borchmann, Joseph P McGuirk, Ulrich Jäger, Samantha Jaglowski, Charalambos Andreadis, Jason R Westin,[...]. N Engl J Med 2019
52
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
Sattva S Neelapu, Frederick L Locke, Nancy L Bartlett, Lazaros J Lekakis, David B Miklos, Caron A Jacobson, Ira Braunschweig, Olalekan O Oluwole, Tanya Siddiqi, Yi Lin,[...]. N Engl J Med 2017
Sattva S Neelapu, Frederick L Locke, Nancy L Bartlett, Lazaros J Lekakis, David B Miklos, Caron A Jacobson, Ira Braunschweig, Olalekan O Oluwole, Tanya Siddiqi, Yi Lin,[...]. N Engl J Med 2017
51
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.
Michael Crump, Sattva S Neelapu, Umar Farooq, Eric Van Den Neste, John Kuruvilla, Jason Westin, Brian K Link, Annette Hay, James R Cerhan, Liting Zhu,[...]. Blood 2017
Michael Crump, Sattva S Neelapu, Umar Farooq, Eric Van Den Neste, John Kuruvilla, Jason Westin, Brian K Link, Annette Hay, James R Cerhan, Liting Zhu,[...]. Blood 2017
42
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.
Nagesh Kalakonda, Marie Maerevoet, Federica Cavallo, George Follows, Andre Goy, Joost S P Vermaat, Olivier Casasnovas, Nada Hamad, Josée M Zijlstra, Sameer Bakhshi,[...]. Lancet Haematol 2020
Nagesh Kalakonda, Marie Maerevoet, Federica Cavallo, George Follows, Andre Goy, Joost S P Vermaat, Olivier Casasnovas, Nada Hamad, Josée M Zijlstra, Sameer Bakhshi,[...]. Lancet Haematol 2020
38
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Jeremy S Abramson, M Lia Palomba, Leo I Gordon, Matthew A Lunning, Michael Wang, Jon Arnason, Amitkumar Mehta, Enkhtsetseg Purev, David G Maloney, Charalambos Andreadis,[...]. Lancet 2020
Jeremy S Abramson, M Lia Palomba, Leo I Gordon, Matthew A Lunning, Michael Wang, Jon Arnason, Amitkumar Mehta, Enkhtsetseg Purev, David G Maloney, Charalambos Andreadis,[...]. Lancet 2020
36
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Frederick L Locke, Armin Ghobadi, Caron A Jacobson, David B Miklos, Lazaros J Lekakis, Olalekan O Oluwole, Yi Lin, Ira Braunschweig, Brian T Hill, John M Timmerman,[...]. Lancet Oncol 2019
Frederick L Locke, Armin Ghobadi, Caron A Jacobson, David B Miklos, Lazaros J Lekakis, Olalekan O Oluwole, Yi Lin, Ira Braunschweig, Brian T Hill, John M Timmerman,[...]. Lancet Oncol 2019
32
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
Christian Gisselbrecht, Bertram Glass, Nicolas Mounier, Devinder Singh Gill, David C Linch, Marek Trneny, Andre Bosly, Nicolas Ketterer, Ofer Shpilberg, Hans Hagberg,[...]. J Clin Oncol 2010
Christian Gisselbrecht, Bertram Glass, Nicolas Mounier, Devinder Singh Gill, David C Linch, Marek Trneny, Andre Bosly, Nicolas Ketterer, Ofer Shpilberg, Hans Hagberg,[...]. J Clin Oncol 2010
30
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.
Paolo F Caimi, Weiyun Ai, Juan Pablo Alderuccio, Kirit M Ardeshna, Mehdi Hamadani, Brian Hess, Brad S Kahl, John Radford, Melhem Solh, Anastasios Stathis,[...]. Lancet Oncol 2021
Paolo F Caimi, Weiyun Ai, Juan Pablo Alderuccio, Kirit M Ardeshna, Mehdi Hamadani, Brian Hess, Brad S Kahl, John Radford, Melhem Solh, Anastasios Stathis,[...]. Lancet Oncol 2021
51
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Bertrand Coiffier, Eric Lepage, Josette Briere, Raoul Herbrecht, Hervé Tilly, Reda Bouabdallah, Pierre Morel, Eric Van Den Neste, Gilles Salles, Philippe Gaulard,[...]. N Engl J Med 2002
Bertrand Coiffier, Eric Lepage, Josette Briere, Raoul Herbrecht, Hervé Tilly, Reda Bouabdallah, Pierre Morel, Eric Van Den Neste, Gilles Salles, Philippe Gaulard,[...]. N Engl J Med 2002
24
Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
W Jurczak, P L Zinzani, G Gaidano, A Goy, M Provencio, Z Nagy, T Robak, K Maddocks, C Buske, S Ambarkhane,[...]. Ann Oncol 2018
W Jurczak, P L Zinzani, G Gaidano, A Goy, M Provencio, Z Nagy, T Robak, K Maddocks, C Buske, S Ambarkhane,[...]. Ann Oncol 2018
30
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.
Bertrand Coiffier, Catherine Thieblemont, Eric Van Den Neste, Gérard Lepeu, Isabelle Plantier, Sylvie Castaigne, Sophie Lefort, Gérald Marit, Margaret Macro, Catherine Sebban,[...]. Blood 2010
Bertrand Coiffier, Catherine Thieblemont, Eric Van Den Neste, Gérard Lepeu, Isabelle Plantier, Sylvie Castaigne, Sophie Lefort, Gérald Marit, Margaret Macro, Catherine Sebban,[...]. Blood 2010
19
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).
Franck Morschhauser, Ian W Flinn, Ranjana Advani, Laurie H Sehn, Catherine Diefenbach, Kathryn Kolibaba, Oliver W Press, Gilles Salles, Hervé Tilly, Andy I Chen,[...]. Lancet Haematol 2019
Franck Morschhauser, Ian W Flinn, Ranjana Advani, Laurie H Sehn, Catherine Diefenbach, Kathryn Kolibaba, Oliver W Press, Gilles Salles, Hervé Tilly, Andy I Chen,[...]. Lancet Haematol 2019
18
Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12.
Michael Crump, John Kuruvilla, Stephen Couban, David A MacDonald, Vishal Kukreti, C Tom Kouroukis, Morel Rubinger, Rena Buckstein, Kevin R Imrie, Massimo Federico,[...]. J Clin Oncol 2014
Michael Crump, John Kuruvilla, Stephen Couban, David A MacDonald, Vishal Kukreti, C Tom Kouroukis, Morel Rubinger, Rena Buckstein, Kevin R Imrie, Massimo Federico,[...]. J Clin Oncol 2014
18
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma.
Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo F Caimi, Erin Reid, Owen A O'Connor, Jay M Feingold, Kirit M Ardeshna, William Townsend, Melhem Solh,[...]. Blood 2021
Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo F Caimi, Erin Reid, Owen A O'Connor, Jay M Feingold, Kirit M Ardeshna, William Townsend, Melhem Solh,[...]. Blood 2021
43
Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma.
Andreas Viardot, Marie-Elisabeth Goebeler, Georg Hess, Svenja Neumann, Michael Pfreundschuh, Nicole Adrian, Florian Zettl, Martin Libicher, Cyrus Sayehli, Julia Stieglmaier,[...]. Blood 2016
Andreas Viardot, Marie-Elisabeth Goebeler, Georg Hess, Svenja Neumann, Michael Pfreundschuh, Nicole Adrian, Florian Zettl, Martin Libicher, Cyrus Sayehli, Julia Stieglmaier,[...]. Blood 2016
17
Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
Holly M Horton, Matthew J Bernett, Erik Pong, Matthias Peipp, Sher Karki, Seung Y Chu, John O Richards, Igor Vostiar, Patrick F Joyce, Roland Repp,[...]. Cancer Res 2008
Holly M Horton, Matthew J Bernett, Erik Pong, Matthias Peipp, Sher Karki, Seung Y Chu, John O Richards, Igor Vostiar, Patrick F Joyce, Roland Repp,[...]. Cancer Res 2008
17
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.
Bruce D Cheson, Richard I Fisher, Sally F Barrington, Franco Cavalli, Lawrence H Schwartz, Emanuele Zucca, T Andrew Lister. J Clin Oncol 2014
Bruce D Cheson, Richard I Fisher, Sally F Barrington, Franco Cavalli, Lawrence H Schwartz, Emanuele Zucca, T Andrew Lister. J Clin Oncol 2014
16
The 2016 revision of the World Health Organization classification of lymphoid neoplasms.
Steven H Swerdlow, Elias Campo, Stefano A Pileri, Nancy Lee Harris, Harald Stein, Reiner Siebert, Ranjana Advani, Michele Ghielmini, Gilles A Salles, Andrew D Zelenetz,[...]. Blood 2016
Steven H Swerdlow, Elias Campo, Stefano A Pileri, Nancy Lee Harris, Harald Stein, Reiner Siebert, Ranjana Advani, Michele Ghielmini, Gilles A Salles, Andrew D Zelenetz,[...]. Blood 2016
16
Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.
Anas Younes, Laurie H Sehn, Peter Johnson, Pier Luigi Zinzani, Xiaonan Hong, Jun Zhu, Caterina Patti, David Belada, Olga Samoilova, Cheolwon Suh,[...]. J Clin Oncol 2019
Anas Younes, Laurie H Sehn, Peter Johnson, Pier Luigi Zinzani, Xiaonan Hong, Jun Zhu, Caterina Patti, David Belada, Olga Samoilova, Cheolwon Suh,[...]. J Clin Oncol 2019
16
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
Martin Hutchings, Franck Morschhauser, Gloria Iacoboni, Carmelo Carlo-Stella, Fritz C Offner, Anna Sureda, Gilles Salles, Joaquín Martínez-Lopez, Michael Crump, Denise N Thomas,[...]. J Clin Oncol 2021
Martin Hutchings, Franck Morschhauser, Gloria Iacoboni, Carmelo Carlo-Stella, Fritz C Offner, Anna Sureda, Gilles Salles, Joaquín Martínez-Lopez, Michael Crump, Denise N Thomas,[...]. J Clin Oncol 2021
23
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.
Wyndham H Wilson, Ryan M Young, Roland Schmitz, Yandan Yang, Stefania Pittaluga, George Wright, Chih-Jian Lih, P Mickey Williams, Arthur L Shaffer, John Gerecitano,[...]. Nat Med 2015
Wyndham H Wilson, Ryan M Young, Roland Schmitz, Yandan Yang, Stefania Pittaluga, George Wright, Chih-Jian Lih, P Mickey Williams, Arthur L Shaffer, John Gerecitano,[...]. Nat Med 2015
15
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
T Philip, C Guglielmi, A Hagenbeek, R Somers, H Van der Lelie, D Bron, P Sonneveld, C Gisselbrecht, J Y Cahn, J L Harousseau. N Engl J Med 1995
T Philip, C Guglielmi, A Hagenbeek, R Somers, H Van der Lelie, D Bron, P Sonneveld, C Gisselbrecht, J Y Cahn, J L Harousseau. N Engl J Med 1995
15
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.
Loretta J Nastoupil, Michael D Jain, Lei Feng, Jay Y Spiegel, Armin Ghobadi, Yi Lin, Saurabh Dahiya, Matthew Lunning, Lazaros Lekakis, Patrick Reagan,[...]. J Clin Oncol 2020
Loretta J Nastoupil, Michael D Jain, Lei Feng, Jay Y Spiegel, Armin Ghobadi, Yi Lin, Saurabh Dahiya, Matthew Lunning, Lazaros Lekakis, Patrick Reagan,[...]. J Clin Oncol 2020
14
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.
Eric D Jacobsen, Jeff P Sharman, Yasuhiro Oki, Ranjana H Advani, Jane N Winter, Celeste M Bello, Gary Spitzer, Maria Corinna Palanca-Wessels, Dana A Kennedy, Pamela Levine,[...]. Blood 2015
Eric D Jacobsen, Jeff P Sharman, Yasuhiro Oki, Ranjana H Advani, Jane N Winter, Celeste M Bello, Gary Spitzer, Maria Corinna Palanca-Wessels, Dana A Kennedy, Pamela Levine,[...]. Blood 2015
14
CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy.
Bicky Thapa, Paolo F Caimi, Kirit M Ardeshna, Melhem Solh, Carmelo Carlo-Stella, Brad S Kahl, Mehdi Hamadani. Blood Adv 2020
Bicky Thapa, Paolo F Caimi, Kirit M Ardeshna, Melhem Solh, Carmelo Carlo-Stella, Brad S Kahl, Mehdi Hamadani. Blood Adv 2020
54
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Maria Corinna A Palanca-Wessels, Myron Czuczman, Gilles Salles, Sarit Assouline, Laurie H Sehn, Ian Flinn, Manish R Patel, Randeep Sangha, Anton Hagenbeek, Ranjana Advani,[...]. Lancet Oncol 2015
Maria Corinna A Palanca-Wessels, Myron Czuczman, Gilles Salles, Sarit Assouline, Laurie H Sehn, Ian Flinn, Manish R Patel, Randeep Sangha, Anton Hagenbeek, Ranjana Advani,[...]. Lancet Oncol 2015
13
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.
Nancy L Bartlett, Wyndham H Wilson, Sin-Ho Jung, Eric D Hsi, Matthew J Maurer, Levi D Pederson, Mei-Yin C Polley, Brandelyn N Pitcher, Bruce D Cheson, Brad S Kahl,[...]. J Clin Oncol 2019
Nancy L Bartlett, Wyndham H Wilson, Sin-Ho Jung, Eric D Hsi, Matthew J Maurer, Levi D Pederson, Mei-Yin C Polley, Brandelyn N Pitcher, Bruce D Cheson, Brad S Kahl,[...]. J Clin Oncol 2019
13
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
Maria-Elisabeth Goebeler, Stefan Knop, Andreas Viardot, Peter Kufer, Max S Topp, Hermann Einsele, Richard Noppeney, Georg Hess, Stefan Kallert, Andreas Mackensen,[...]. J Clin Oncol 2016
Maria-Elisabeth Goebeler, Stefan Knop, Andreas Viardot, Peter Kufer, Max S Topp, Hermann Einsele, Richard Noppeney, Georg Hess, Stefan Kallert, Andreas Mackensen,[...]. J Clin Oncol 2016
13
Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial.
Nicolas Mounier, Taoufik El Gnaoui, Hervé Tilly, Danièle Canioni, Catherine Sebban, René-Olivier Casasnovas, Richard Delarue, Anne Sonet, Pauline Beaussart, Tony Petrella,[...]. Haematologica 2013
Nicolas Mounier, Taoufik El Gnaoui, Hervé Tilly, Danièle Canioni, Catherine Sebban, René-Olivier Casasnovas, Richard Delarue, Anne Sonet, Pauline Beaussart, Tony Petrella,[...]. Haematologica 2013
13
An unexpected error occurred.
Please provide the following information to technical support:
Error Event: onRequest
Error details:
struct | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cause |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Detail | An exception occurred while invoking an event handler method from Application.cfc. The method name is: onRequest. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Message | Event handler exception. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
RootCause |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
StackTrace | coldfusion.runtime.EventHandlerException: Event handler exception. at coldfusion.runtime.AppEventInvoker.onRequest(AppEventInvoker.java:319) at coldfusion.filter.ApplicationFilter.invoke(ApplicationFilter.java:551) at coldfusion.filter.RequestMonitorFilter.invoke(RequestMonitorFilter.java:43) at coldfusion.filter.MonitoringFilter.invoke(MonitoringFilter.java:40) at coldfusion.filter.PathFilter.invoke(PathFilter.java:162) at coldfusion.filter.IpFilter.invoke(IpFilter.java:45) at coldfusion.filter.ExceptionFilter.invoke(ExceptionFilter.java:96) at coldfusion.filter.ClientScopePersistenceFilter.invoke(ClientScopePersistenceFilter.java:28) at coldfusion.filter.BrowserFilter.invoke(BrowserFilter.java:38) at coldfusion.filter.NoCacheFilter.invoke(NoCacheFilter.java:60) at coldfusion.filter.GlobalsFilter.invoke(GlobalsFilter.java:38) at coldfusion.filter.DatasourceFilter.invoke(DatasourceFilter.java:22) at coldfusion.filter.CachingFilter.invoke(CachingFilter.java:62) at coldfusion.CfmServlet.service(CfmServlet.java:226) at coldfusion.bootstrap.BootstrapServlet.service(BootstrapServlet.java:311) at org.apache.catalina.core.ApplicationFilterChain.internalDoFilter(ApplicationFilterChain.java:228) at org.apache.catalina.core.ApplicationFilterChain.doFilter(ApplicationFilterChain.java:163) at coldfusion.monitor.event.MonitoringServletFilter.doFilter(MonitoringServletFilter.java:46) at coldfusion.bootstrap.BootstrapFilter.doFilter(BootstrapFilter.java:47) at org.apache.catalina.core.ApplicationFilterChain.internalDoFilter(ApplicationFilterChain.java:190) at org.apache.catalina.core.ApplicationFilterChain.doFilter(ApplicationFilterChain.java:163) at org.apache.tomcat.websocket.server.WsFilter.doFilter(WsFilter.java:53) at org.apache.catalina.core.ApplicationFilterChain.internalDoFilter(ApplicationFilterChain.java:190) at org.apache.catalina.core.ApplicationFilterChain.doFilter(ApplicationFilterChain.java:163) at org.apache.catalina.core.StandardWrapperValve.invoke(StandardWrapperValve.java:202) at org.apache.catalina.core.StandardContextValve.invoke(StandardContextValve.java:97) at org.apache.catalina.authenticator.AuthenticatorBase.invoke(AuthenticatorBase.java:542) at org.apache.catalina.core.StandardHostValve.invoke(StandardHostValve.java:143) at org.apache.catalina.valves.ErrorReportValve.invoke(ErrorReportValve.java:92) at org.apache.catalina.core.StandardEngineValve.invoke(StandardEngineValve.java:78) at org.apache.catalina.connector.CoyoteAdapter.service(CoyoteAdapter.java:373) at org.apache.coyote.ajp.AjpProcessor.service(AjpProcessor.java:462) at org.apache.coyote.AbstractProcessorLight.process(AbstractProcessorLight.java:65) at org.apache.coyote.AbstractProtocol$ConnectionHandler.process(AbstractProtocol.java:893) at org.apache.tomcat.util.net.NioEndpoint$SocketProcessor.doRun(NioEndpoint.java:1723) at org.apache.tomcat.util.net.SocketProcessorBase.run(SocketProcessorBase.java:49) at java.base/java.util.concurrent.ThreadPoolExecutor.runWorker(ThreadPoolExecutor.java:1128) at java.base/java.util.concurrent.ThreadPoolExecutor$Worker.run(ThreadPoolExecutor.java:628) at org.apache.tomcat.util.threads.TaskThread$WrappingRunnable.run(TaskThread.java:61) at java.base/java.lang.Thread.run(Thread.java:834) Caused by: coldfusion.runtime.UDFMethod$InvalidArgumentTypeException: The COCITEDARTICLECITATION_COUNT argument passed to the calculArticleSimilarity function is not of type numeric. at coldfusion.runtime.UDFMethod._validateArgWithValidator(UDFMethod.java:1434) at coldfusion.runtime.UDFMethod._validateRequiredArg(UDFMethod.java:1400) at cfpubmed2ecfc1897273376$funcCALCULARTICLESIMILARITY.runFunction(C:\home\cocites.com\wwwroot\cfc\pubmed.cfc:215) at coldfusion.runtime.UDFMethod.invoke(UDFMethod.java:554) at coldfusion.runtime.UDFMethod$ReturnTypeFilter.invoke(UDFMethod.java:485) at coldfusion.runtime.UDFMethod$ArgumentCollectionFilter.invoke(UDFMethod.java:448) at coldfusion.filter.FunctionAccessFilter.invoke(FunctionAccessFilter.java:95) at coldfusion.runtime.UDFMethod.runFilterChain(UDFMethod.java:399) at coldfusion.runtime.UDFMethod.runFilterChain(UDFMethod.java:372) at coldfusion.runtime.UDFMethod.invoke(UDFMethod.java:288) at coldfusion.runtime.TemplateProxy.invoke(TemplateProxy.java:830) at coldfusion.runtime.TemplateProxy.invoke(TemplateProxy.java:613) at coldfusion.runtime.TemplateProxy.invoke(TemplateProxy.java:438) at coldfusion.runtime.CfJspPage._invoke(CfJspPage.java:3627) at coldfusion.runtime.CfJspPage._invoke(CfJspPage.java:3604) at cfcoCitedArticles2ecfm1072712._factor11(C:\home\cocites.com\wwwroot\coCitedArticles.cfm:483) at cfcoCitedArticles2ecfm1072712._factor14(C:\home\cocites.com\wwwroot\coCitedArticles.cfm:401) at cfcoCitedArticles2ecfm1072712._factor15(C:\home\cocites.com\wwwroot\coCitedArticles.cfm:321) at cfcoCitedArticles2ecfm1072712._factor17(C:\home\cocites.com\wwwroot\coCitedArticles.cfm:298) at cfcoCitedArticles2ecfm1072712.runPage(C:\home\cocites.com\wwwroot\coCitedArticles.cfm:1) at coldfusion.runtime.CfJspPage.invoke(CfJspPage.java:262) at coldfusion.tagext.lang.IncludeTag.handlePageInvoke(IncludeTag.java:735) at coldfusion.tagext.lang.IncludeTag.doStartTag(IncludeTag.java:565) at coldfusion.runtime.CfJspPage._emptyTcfTag(CfJspPage.java:4329) at cfApplication2ecfc1402755519$funcONREQUEST.runFunction(C:\home\cocites.com\wwwroot\Application.cfc:182) at coldfusion.runtime.UDFMethod.invoke(UDFMethod.java:554) at coldfusion.runtime.UDFMethod$ReturnTypeFilter.invoke(UDFMethod.java:485) at coldfusion.runtime.UDFMethod$ArgumentCollectionFilter.invoke(UDFMethod.java:448) at coldfusion.filter.FunctionAccessFilter.invoke(FunctionAccessFilter.java:95) at coldfusion.runtime.UDFMethod.runFilterChain(UDFMethod.java:399) at coldfusion.runtime.UDFMethod.runFilterChain(UDFMethod.java:372) at coldfusion.runtime.UDFMethod.invoke(UDFMethod.java:288) at coldfusion.runtime.TemplateProxy.invoke(TemplateProxy.java:830) at coldfusion.runtime.TemplateProxy.invoke(TemplateProxy.java:613) at coldfusion.runtime.TemplateProxy.invoke(TemplateProxy.java:438) at coldfusion.runtime.AppEventInvoker.invoke(AppEventInvoker.java:115) at coldfusion.runtime.AppEventInvoker.onRequest(AppEventInvoker.java:308) ... 39 more | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Suppressed |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TagContext |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Type | Application | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
name | onRequest |